Dantrolene is neuroprotective in Huntington's disease transgenic mouse model

被引：0
|
作者：
Xi Chen
Jun Wu
Svetlana Lvovskaya
Emily Herndon
Charlene Supnet
Ilya Bezprozvanny
机构：
[1] University of Texas Southwestern Medical Center at Dallas,Department of Physiology
[2] St Petersburg State Polytechnical University,Department of Medical Physics and Bioengineering
[3] University of Texas Southwestern Medical Center at Dallas,Department of Pathology
来源：
Molecular Neurodegeneration | / 6卷
关键词：
Huntington's disease; calcium signaling; calcium imaging; cell death; dantrolene; ryanodine receptor; aggregation; neuroprotection;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Laquinimod treatment in a mouse model of Huntington's disease: A new neuroprotective therapy?
    Ellrichmann, Gisa
    Reick, Christiane
    Saft, Carsten
    Thoene, Jan
    Hayardeny, Liat
    Gold, Ralf
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2014, 275 (1-2) : 217 - 218
  • [22] A fully humanized transgenic mouse model of Huntington disease
    Southwell, Amber L.
    Warby, Simon C.
    Carroll, Jeffrey B.
    Doty, Crystal N.
    Skotte, Niels H.
    Zhang, Weining
    Villanueva, Erika B.
    Kovalik, Vlad
    Xie, Yuanyun
    Pouladi, Mahmoud A.
    Collins, Jennifer A.
    Yang, X. William
    Franciosi, Sonia
    Hayden, Michael R.
    [J]. HUMAN MOLECULAR GENETICS, 2013, 22 (01) : 18 - 34
  • [23] Safety of Striatal Infusion of siRNA in a Transgenic Huntington's Disease Mouse Model
    Johnson, Emily
    Chase, Kathryn
    McGowan, Sarah
    Mondo, Erica
    Pfister, Edith
    Mick, Eric
    Friedline, Randall H.
    Kim, Jason K.
    Sapp, Ellen
    DiFiglia, Marian
    Aronin, Neil
    [J]. JOURNAL OF HUNTINGTONS DISEASE, 2015, 4 (03) : 219 - 229
  • [24] Ataxic Symptoms in Huntington's Disease Transgenic Mouse Model Are Alleviated by Chlorzoxazone
    Egorova, Polina A.
    Gavrilova, Aleksandra V.
    Bezprozvanny, Ilya B.
    [J]. FRONTIERS IN NEUROSCIENCE, 2020, 14
  • [25] Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease
    Morton, AJ
    Edwardson, JM
    [J]. JOURNAL OF NEUROCHEMISTRY, 2001, 76 (01) : 166 - 172
  • [26] Transgenic Mouse Models of Parkinson's Disease and Huntington's Disease
    Skaper, Stephen D.
    Giusti, Pietro
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (04) : 455 - 470
  • [27] Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease
    Renoir, Thibault
    Argyropoulos, Andrew
    Chevarin, Caroline
    Lanfumey, Laurence
    Hannan, Anthony J.
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2014, 127 : 15 - 20
  • [28] Neuroinflammation in the YAC128 transgenic mouse model of Huntington's disease
    Connolly, C.
    Thiele, J.
    Beck, J.
    Lefroy, C.
    Hill, A.
    Leavitt, B. R.
    [J]. MOVEMENT DISORDERS, 2012, 27 : S58 - S58
  • [29] Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease
    Kiriazis, Helen
    Jennings, Nicole L.
    Davern, Pamela
    Lambert, Gavin
    Su, Yidan
    Pang, Terence
    Du, Xin
    La Greca, Luisa
    Head, Geoffrey A.
    Hannan, Anthony J.
    Du, Xiao-Jun
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 2012, 590 (22): : 5845 - 5860
  • [30] Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease
    Bogdanov, MB
    Andreassen, OA
    Dedeoglu, A
    Ferrante, RJ
    Beal, MF
    [J]. JOURNAL OF NEUROCHEMISTRY, 2001, 79 (06) : 1246 - 1249
12345